As a medical expert with a focus on cardiology, I have spent years studying the intricacies of heart function and the impact of various treatments on cardiovascular health. The ejection fraction, a critical measure of the heart's ability to pump blood effectively, is often a key indicator in assessing heart health. When it comes to the question of whether drugs can improve ejection fraction, the answer is nuanced and requires a comprehensive understanding of the pharmacological interventions available.

ACE inhibitors or ARBs, in conjunction with beta blockers, are cornerstones in the treatment of heart failure and conditions that affect the ejection fraction. These medications work synergistically to reduce the stress hormones that can exacerbate the weakening of the heart muscle and the progression of heart disease. By doing so, they help to mitigate the adverse effects of these hormones on the heart's function.

ACE inhibitors, or Angiotensin-Converting Enzyme inhibitors, work by blocking the enzyme that converts angiotensin I to angiotensin II, a potent vasoconstrictor. This leads to vasodilation, reducing the workload on the heart and lowering blood pressure. ARBs, or Angiotensin Receptor Blockers, serve a similar function by directly blocking the angiotensin II receptor, preventing the vasoconstrictive and negative remodeling effects of angiotensin II on the heart.

Beta blockers, on the other hand, slow down the heart rate and reduce the force of heart contractions. This reduction in cardiac demand helps to decrease the oxygen consumption of the heart, which is particularly beneficial in conditions where the heart is already compromised.

The statement that "Everyone with low EF should be on both medications, if they can tolerate them" reflects the general consensus among healthcare professionals that these drug classes are beneficial for patients with reduced ejection fraction. However, it is important to note that treatment must be individualized, taking into account the patient's overall health, the severity of their condition, and any potential contraindications or side effects.

It is also worth mentioning that while these drugs can help manage and improve symptoms and outcomes in patients with reduced ejection fraction, they are not a cure-all. Lifestyle modifications, such as a heart-healthy diet, regular exercise (as tolerated), and avoiding smoking and excessive alcohol consumption, are also crucial components of comprehensive heart health management.

In conclusion, while ACE inhibitors, ARBs, and beta blockers can indeed improve ejection fraction in many patients, it is essential to approach treatment with a holistic view, considering both pharmacological and lifestyle interventions. The goal is to improve the heart's function and overall quality of life for the patient.

read more >>

ACE inhibitors or ARBs, plus beta blockers. These drugs reduce stress hormones that can cause further weakening of the heart muscle and disease progression. They also decrease the amount of work required for the heart to pump effectively. "Everyone with low EF should be on both medications, if they can tolerate them.Oct 1, 2012read more >>